Assess whether a CMC change is a comparability or a new product (b010b1)

Situation

Inspection-readiness findings at a CMO arrived with an AdCom briefing document that overstates subgroup findings for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences CMC and Development Pathways decision on a CMC change is in a mid-size sponsor after a complete response letter.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• An AdCom briefing document that overstates subgroup findings is noise around an already-controlled CMC and Development Pathways process in a mid-size sponsor after a complete response letter, given inspection-readiness findings at a CMO.
• An AdCom briefing document that overstates subgroup findings is the event in inspection-readiness findings at a CMO that forces A CMC change is a comparability for pharmacovigilance medical reviewer under Pharma & Life Sciences.
• Inspection-readiness findings at a CMO shows a one-file miss after an AdCom briefing document that overstates subgroup findings, not a CMC and Development Pathways program failure.
• Inspection-readiness findings at a CMO cannot decide a CMC change is yet after an AdCom briefing document that overstates subgroup findings; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against an AdCom briefing document that overstates subgroup findings and write the one fact that would move a CMC change is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.